BioMed Research International

BioMed Research International / 2002 / Article
Special Issue

DNA Damage, Repair, and Diseases

View this Special Issue

Review article | Open Access

Volume 2 |Article ID 371845 |

Henning Willers, Fen Xia, Simon N. Powell, "Recombinational DNA Repair in Cancer and Normal Cells: The Challenge of Functional Analysis", BioMed Research International, vol. 2, Article ID 371845, 8 pages, 2002.

Recombinational DNA Repair in Cancer and Normal Cells: The Challenge of Functional Analysis

Received29 Nov 2001
Revised28 Feb 2002
Accepted05 Mar 2002


A major goal of current cancer research is to understand the functional consequences of mutations in recombinational DNA repair genes. The introduction of artificial recombination substrates into living cells has evolved into a powerful tool to perform functional analysis of DNA double strand break (DSB) repair. Here, we review the principles and practice of current plasmid assays with regard to the two major DSB repair pathways, homologous recombination and nonhomologous end-joining. A spectrum of assay types is available to assess repair in a wide variety of cell lines. However, several technical challenges still need to be overcome. Understanding the alterations of DSB repair in cancers will ultimately provide a rational basis for drug design that may selectively sensitize tumor cells to ionizing radiation and chemotherapy, thereby achieving therapeutic gain.

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.